Krzysztof Gawrychowski
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Krzysztof Gawrychowski has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Maciej Małecki
Department of Applied Pharmacy, Faculty of Pharmacy, Medical University of Warsaw, 02-097 Warsaw, Poland
3 shared publications - Agnieszka Zajkowska
Med Univ Warsaw, Dept Appl Pharm, Fac Pharm, Warsaw, Poland
1 shared publication - Aleksandra Banaszkiewicz
Department of Pediatric Gastroenterology and Nutrition, Medical University of Warsaw, 02-091 Warsaw, Poland
1 shared publication - Alicja Bieńkowska
Department of Applied Pharmacy, Faculty of Pharmacy, Medical University of Warsaw, 1 Banacha Street, 02-097 Warsaw, Poland
1 shared publication - Arkadiusz Leloch1 shared publication
- Iga Osińska1 shared publication
Latest Publications
- Open Access
- 29 September 2023
- Published by Wroclaw Medical University in Advances in Clinical and Experimental Medicine
- Vol. 32 (10) , 1201-1210
Profiling of microRNA as a tool to introduce rAAV vectors in gene therapy of breast cancer: A preliminary report
Background. Despite the wide range of diagnostic and therapeutic methods, breast cancer is responsible for many deaths each year. One of the original and novel cancer therapeutic approaches is gene therapy based on recombinant adeno-associated viral vectors. Among the molecular factors with the potential to become useful diagnostic biomarkers, microRNA (miRNA) molecules are being considered for personalized therapies. Objectives. The aim of the study was to examine the utility of miRNA profiling in the design of personalized recombinant adeno-associated virus (rAAV)-based gene therapy for breast cancer patients. Materials and methods. The analysis of 754 miRNAs in 7 breast cancer samples and control samples was performed using real-time polymerase chain reaction (PCR) based on TaqMan (R) Low-density Array (TLDA) cards. Online repositories were used to explore the relationship between miRNAs and genes encoding rAAV receptors (KIAA0319L, HSPG2, FGFR1, c-MET, PDGFRA, ITGB5, and RPSA). Then, we performed a comparative analysis of the results to examine the possibility of using miRNA profiling in the design of rAAV-based therapeutic protocols. Results. Fifty-two percent of tested miRNAs were noted in at least 1 analyzed breast cancer and control tissue. Thirteen miRNAs were selected due to being outliers in the tested samples. In total, 155 miRNAs targeted genes encoding rAAV receptors in the tested samples (29 miRNAs for KIAA0319L, 60 miRNAs for c-MET, 31 miRNAs for HSPG2, 43 miRNAs for FGFR1, 36 miRNAs for PDGFRA, 18 miRNAs for RPSA, and 25 miRNAs for ITGB5). The expression of the selected miRNAs was not homogeneous across the 7 samples. Conclusions. Profiling of microRNA could be a significant factor in the design of rAAV-based personalized gene therapy for breast cancer patients.
- 29 September 2023
- Published by Wroclaw Medical University in Advances in Clinical and Experimental Medicine
- Vol. 32 (10) , 1201-1210
Open AccessProfiling of microRNA as a tool to introduce rAAV vectors in gene therapy of breast cancer: A preliminary report
Background. Despite the wide range of diagnostic and therapeutic methods, breast cancer is responsible for many deaths each year. One of the original and novel cancer therapeutic approaches is gene therapy based on recombinant adeno-associated viral vectors. Among the molecular factors with the potential to become useful diagnostic biomarkers, microRNA (miRNA) molecules are being considered for personalized therapies. Objectives. The aim of the study was to examine the utility of miRNA profiling in the design of personalized recombinant adeno-associated virus (rAAV)-based gene therapy for breast cancer patients. Materials and methods. The analysis of 754 miRNAs in 7 breast cancer samples and control samples was performed using real-time polymerase chain reaction (PCR) based on TaqMan (R) Low-density Array (TLDA) cards. Online repositories were used to explore the relationship between miRNAs and genes encoding rAAV receptors (KIAA0319L, HSPG2, FGFR1, c-MET, PDGFRA, ITGB5, and RPSA). Then, we performed a comparative analysis of the results to examine the possibility of using miRNA profiling in the design of rAAV-based therapeutic protocols. Results. Fifty-two percent of tested miRNAs were noted in at least 1 analyzed breast cancer and control tissue. Thirteen miRNAs were selected due to being outliers in the tested samples. In total, 155 miRNAs targeted genes encoding rAAV receptors in the tested samples (29 miRNAs for KIAA0319L, 60 miRNAs for c-MET, 31 miRNAs for HSPG2, 43 miRNAs for FGFR1, 36 miRNAs for PDGFRA, 18 miRNAs for RPSA, and 25 miRNAs for ITGB5). The expression of the selected miRNAs was not homogeneous across the 7 samples. Conclusions. Profiling of microRNA could be a significant factor in the design of rAAV-based personalized gene therapy for breast cancer patients.
- 27 April 2020
- Published by Polish Pharmaceutical Society in Farmacja Polska
- Vol. 76 (3) , 127-136
Pharmaceutical emulsion with increased viscosity for local use of glucocorticosteroids in the esophagus
- 27 April 2020
- Published by Polish Pharmaceutical Society in Farmacja Polska
- Vol. 76 (3) , 127-136
Pharmaceutical emulsion with increased viscosity for local use of glucocorticosteroids in the esophagus
- Open Access
- 1 January 2020
- Published by Polish Pharmaceutical Society in Farmacja Polska
- Vol. 76 (12) , 667-675
Neurotransfection activity of gene preparations: introduction to dressing formulations
- 1 January 2020
- Published by Polish Pharmaceutical Society in Farmacja Polska
- Vol. 76 (12) , 667-675
Open AccessNeurotransfection activity of gene preparations: introduction to dressing formulations